Text Size

A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

This study has been completed.
Sponsor:
Collaborators:
Bristol-Myers Squibb
Sanofi
Information provided by:
Veeda Oncology
ClinicalTrials.gov Identifier:
NCT00251485
First received: November 8, 2005
Last updated: August 20, 2008
Last verified: August 2008
History of Changes
  Purpose

This is a Phase II, open label, non-randomized study in patients with histologically or pathologically confirmed diagnosis of stage IIIB/IV, EGFR+ adenocarcinoma of the colon or rectum who have not received prior chemotherapy for their metastatic disease.

Primary Study Endpoint:

To assess the response rate, progression-free survival, and overall safety profile of a modified FOLFOX 6 plus cetuximab regimen in the first-line treatment of patients with metastatic colorectal cancer.

Secondary Study Endpoint(s):

To assess overall survival of patients with metastatic colorectal cancer who receive first-line therapy with a modified FOLFOX 6 + cetuximab regimen.


Condition Intervention Phase
Colorectal Cancer
 Drug: Cetuximab
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Resource links provided by NLM:

Drug Information available for: Cetuximab
U.S. FDA Resources

Further study details as provided by Veeda Oncology:

Primary Outcome Measures:
  • To assess the response rate, progression-free survival, and overall safety profile of a modified FOLFOX 6 plus cetuximab regimen in the first-line treatment of patients with metastatic colorectal cancer. [ Time Frame: unk ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess overall survival of patients with metastatic colorectal cancer who receive first-line therapy with a modified FOLFOX 6 + cetuximab regimen [ Time Frame: unk ] [ Designated as safety issue: No ]

Enrollment: 82
Study Start Date: March 2004
Study Completion Date: June 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Cetuximab
    Cycle 1: 400 mg/m2 (given as a 2-hour infusion) on Day 1, then 250 mg/m2, Day 8 (given as a 1-hour infusion) subsequent cycles:250 mg/m2, Day 1 and Day 8 (given as a 1-hour infusion)
Detailed Description:

The current treatment options for metastatic colon cancer are in need of further improvement. The three-drug combination of oxaliplatin with 5-FU/LV for the first-line treatment of metastatic colorectal cancer has shown a significant increase in response rate compared to IFL (irinotecan and bolus 5-FU plus leucovorin ) and IROX (irinotecan plus oxaliplatin. Cetuximab has shown activity with and without irinotecan in subjects with colorectal cancer refractory to irinotecan alone.30,31 Cetuximab has also been shown to be safe and effective when administered with infusional 5-FU/folinic acid plus irinotecan. These results suggest that the addition of cetuximab to a 5-FU/LV/oxaliplatin-based regimen (FOLFOX) used in the 1st line setting may lead to the development of more treatment options for subjects with advanced colorectal cancer.

This is a Phase II, open label, non-randomized study in patients with histologically or pathologically confirmed diagnosis of stage IIIB/IV, EGFR+ adenocarcinoma of the colon or rectum who have not received prior chemotherapy for their metastatic disease.

Patients will receive a modified FOLFOX 6 regimen (5-FU, leucovorin, and oxaliplatin) every 2 weeks in combination with cetuximab given weekly.

Patients will be evaluated for response and progression-free survival. Overall survival will also be evaluated, as well as the safety profile of the regimen.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have signed an IRB approved informed consent.
  2. Patients with histologically or pathologically documented, stage IIIB or IV adenocarcinoma of the colon or rectum.
  3. Patients with disease that is not amenable to potentially curative resection (i.e., inoperable metastatic disease).
  4. Patients with tumors that are EGFR + by IHC staining.
  5. Patients with ECOG Performance status of 0 or 1.
  6. Patients, 18 years and older, must either be not of child bearing potential or have a negative serum pregnancy test within 7 days prior to registration. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal.
  7. Bone marrow function: absolute neutrophil count (ANC) > or = 1,500/uL, equivalent to Common Terminology Criteria for Adverse Events (CTCAE, version 3) Grade 1. Platelets > or = 100,000/uL (CTCAE Grade 0 - 1).
  8. Renal function: creatinine < or = 1.5 x institutional upper limit of normal (ULN), CTCAE Grade 1.
  9. Hepatic function: bilirubin < or = 1.5 x ULN, CTCAE Grade 1. AST < or = 2.5 x ULN, CTCAE Grade 1.

Exclusion Criteria:

  1. Patients who received prior chemotherapy for metastatic disease. Prior adjuvant therapy with 5FU/LV and/or irinotecan is allowed provided it was completed at least 6 months prior to enrollment in this study.
  2. Patents who received prior oxaliplatin.
  3. Patients who received prior cetuximab or other therapy which specifically and directly targets the EGF pathway.
  4. Patients with acute hepatitis.
  5. Patients with active or uncontrolled infection.
  6. Patients with a significant history of cardiac disease, i.e., uncontrolled hypertension, unstable angina, and congestive heart failure.
  7. Prior allergic reaction to chimerized or murine monoclonal antibody therapy.
  8. Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent.
  9. Patients with peripheral neuropathy > grade 1
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00251485

Locations
United States, Texas
Veeda Oncology
Houston, Texas, United States, 77042
Sponsors and Collaborators
Veeda Oncology
Bristol-Myers Squibb
Sanofi
Investigators
Principal Investigator: Ralph Boccia, MD Veeda Oncology
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00251485     History of Changes
Other Study ID Numbers: I-03-002
Study First Received: November 8, 2005
Last Updated: August 20, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Veeda Oncology:
Metastatic 1st line colorectal cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
 Colonic Diseases
Intestinal Diseases
Rectal Diseases
Cetuximab
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2013